• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation.

作者信息

Hui Alex Yui, Chan Henry Lik-yuen, Leung Nancy Wai-yee, Hung Lawrence Cheung-tsui, Chan Francis Ka-leung, Sung Joseph Jao-yiu

机构信息

Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong ROC.

出版信息

J Clin Gastroenterol. 2002 May-Jun;34(5):569-72. doi: 10.1097/00004836-200205000-00018.

DOI:10.1097/00004836-200205000-00018
PMID:11960072
Abstract

GOALS

To determine the 2-year survival and prognostic indicators of hepatitis B virus-related cirrhosis after the onset of hepatic decompensation.

BACKGROUND

Chronic hepatitis B (CHB) patients with cirrhosis and resultant hepatic decompensation have reduced survival. However, the natural history of these patients has not been well characterized in previous studies. Better understanding of survival and prognostic indicators is essential in management of these patients, especially in determining who should be candidates for orthotopic liver transplantation.

STUDY

This is a retrospective longitudinal study of 96 patients with CHB-related cirrhosis after the onset of hepatic decompensation. The overall survival was ascertained, and clinical and laboratory variables were analyzed. Significant prognostic indicators for survival at 2 years were determined using univariate and multivariate analyses with Cox regression model.

RESULTS

The overall survival was 80% at 2 years after onset of decompensation. With univariate and multivariate analyses, hepatic encephalopathy and hypoalbuminemia less than 2.8 g/dL were significant prognostic indicators of poor survival probability. The hazard ratios were 5.22 (95% confidence interval, 1.67-16.3) and 8.57 (95% confidence interval, 1.94-37.8), respectively. Patients with hypoalbuminemia less than 2.8 g/dL had a 2-year survival of only 62%.

CONCLUSIONS

Our study showed that of CHB patients who developed the first episode of hepatic decompensation, those with hepatic encephalopathy or significant hypoalbuminemia or both have worse prognoses. They should be considered potential candidates for liver transplantation.

摘要

相似文献

1
Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation.
J Clin Gastroenterol. 2002 May-Jun;34(5):569-72. doi: 10.1097/00004836-200205000-00018.
2
The natural history of hepatitis B virus cirrhosis after the first hepatic decompensation in Tunisia.突尼斯首次肝失代偿后乙肝病毒肝硬化的自然史
Tunis Med. 2012 Feb;90(2):172-6.
3
Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.预测代偿期丙型肝炎病毒(HCV)所致肝硬化患者的死亡风险:一项长期前瞻性研究。
Am J Gastroenterol. 2009 May;104(5):1147-58. doi: 10.1038/ajg.2009.31. Epub 2009 Apr 7.
4
Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.台湾接受拉米夫定治疗的慢性乙型肝炎相关失代偿患者的早期死亡率:终末期肝病模型和指数评分系统作为预后预测指标的评估
Clin Ther. 2006 Dec;28(12):2081-92. doi: 10.1016/j.clinthera.2006.12.016.
5
Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites.因控制腹水而住院的乙型肝炎病毒相关性肝硬化患者的自然病史。
J Gastroenterol Hepatol. 2008 Nov;23(11):1722-7. doi: 10.1111/j.1440-1746.2008.05510.x. Epub 2008 Aug 20.
6
Prognostic significance of hepatic encephalopathy in patients with cirrhosis.肝硬化患者肝性脑病的预后意义
J Hepatol. 1999 May;30(5):890-5. doi: 10.1016/s0168-8278(99)80144-5.
7
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP).366例B型代偿期肝硬化患者的生存及预后因素:一项多中心研究。欧洲病毒性肝炎联合行动组织(EUROHEP)的研究人员。
J Hepatol. 1994 Oct;21(4):656-66. doi: 10.1016/s0168-8278(94)80115-0.
8
Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective.替诺福韦治疗乙型肝炎病毒相关失代偿期肝硬化的生存预测因素:印度视角。
Antiviral Res. 2013 Nov;100(2):300-5. doi: 10.1016/j.antiviral.2013.08.020. Epub 2013 Sep 5.
9
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.肝静脉压力梯度可预测代偿期肝硬化患者的临床失代偿情况。
Gastroenterology. 2007 Aug;133(2):481-8. doi: 10.1053/j.gastro.2007.05.024. Epub 2007 May 21.
10
Development and external validation of a prognostic nomogram for acute decompensation of chronic hepatitis B cirrhosis.慢性乙型肝炎肝硬化急性失代偿预后列线图的开发与外部验证
BMC Gastroenterol. 2018 Dec 3;18(1):179. doi: 10.1186/s12876-018-0911-y.

引用本文的文献

1
Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy.在中国新的按采购量计价政策下,替诺福韦艾拉酚胺在慢性乙型肝炎治疗的成本效益方面优于富马酸替诺福韦二吡呋酯和恩替卡韦。
PLoS One. 2025 Jul 11;20(7):e0327298. doi: 10.1371/journal.pone.0327298. eCollection 2025.
2
Achieving Hepatitis C Micro-Elimination in Chinese Injecting Drug Users: A Dynamic Network Modeling Study.在中国注射吸毒者中实现丙型肝炎微消除:一项动态网络建模研究。
Infect Dis Ther. 2025 Jan;14(1):181-197. doi: 10.1007/s40121-024-01084-0. Epub 2024 Dec 11.
3
Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost-effectiveness analysis.
中国慢性乙型肝炎患者早期肝细胞癌筛查的成本效益分析。
J Comp Eff Res. 2024 Apr;13(4):e230146. doi: 10.57264/cer-2023-0146. Epub 2024 Feb 28.
4
The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study.COVID-19 大流行对男男性行为者中乙型肝炎病毒疫苗接种和传播的影响:一项数学建模研究。
Vaccine. 2022 Aug 5;40(33):4889-4896. doi: 10.1016/j.vaccine.2022.06.075. Epub 2022 Jul 4.
5
Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China.在中国,检测NS5A耐药性以优化艾尔巴韦/格拉瑞韦治疗慢性丙型肝炎的成本效益分析
Front Pharmacol. 2021 Oct 15;12:717504. doi: 10.3389/fphar.2021.717504. eCollection 2021.
6
Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease.慢性乙型肝炎和丙型肝炎的现代抗病毒治疗对肝病临床转归的影响。
World J Gastroenterol. 2021 Aug 7;27(29):4831-4845. doi: 10.3748/wjg.v27.i29.4831.
7
Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective.中国非1型丙型肝炎病毒感染新型抗病毒治疗的成本效益:社会视角
BMJ Glob Health. 2020 Nov;5(11). doi: 10.1136/bmjgh-2020-003194.
8
Clinical Features and Outcomes of Repeated Endoscopic Therapy for Esophagogastric Variceal Hemorrhage in Cirrhotic Patients: Ten-Year Real-World Analysis.肝硬化患者食管胃静脉曲张出血的重复内镜治疗的临床特征及结局:十年真实世界分析
Gastroenterol Res Pract. 2020 May 15;2020:5747563. doi: 10.1155/2020/5747563. eCollection 2020.
9
Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.抗病毒治疗乙型肝炎相关失代偿性肝硬化患者的长期结局。
World J Gastroenterol. 2018 Oct 28;24(40):4606-4614. doi: 10.3748/wjg.v24.i40.4606.
10
Nomogram for cirrhosis in patients with chronic hepatitis B: A simple self-assessed scale for individual risk of cirrhosis.慢性乙型肝炎患者肝硬化的列线图:一种简单的肝硬化个体风险自评量表。
Sci Rep. 2017 Dec 13;7(1):17493. doi: 10.1038/s41598-017-17685-4.